Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912120796> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2912120796 endingPage "AB94" @default.
- W2912120796 startingPage "AB94" @default.
- W2912120796 abstract "Severe asthma (SA) patients have a higher prevalence of comorbid upper airway diseases (UAD) which is associated with difficulty in achieving asthma control, reduced quality of life (QoL), and higher risk of exacerbation. Mepolizumab treatment improves asthma control, QoL and reduces exacerbations in SA patients; this analysis evaluates the efficacy in SA patients with co-morbid UAD. A meta-analysis was conducted in SA patients from the mepolizumab phase 2b/3 clinical program (DREAM, MENSA, SIRIUS, and MUSCA) and investigated patients with self-reported history of comorbid UAD (allergic rhinitis, sinusitis, or nasal polyposis). Mepolizumab’s effect on ACQ, SGRQ, and exacerbations, as compared to placebo in the SA population with and without comorbid UAD. Fifty-nine percent reported at least one upper airway comorbidity, with allergic rhinitis being the most frequent. In SA patients with comorbid UAD and treated with mepolizumab there was a 0.35 (95% CI 0.23, 0.48) improvement in ACQ score, a 7.5 point improvement in SGRQ (95%CI 5.2, 9.8) and a 51% reduction in exacerbations (RR = 0.49; 95%CI 0.41, 0.58) as compared to placebo. In SA patients without comorbid UAD there was a 0.29 (95% CI 0.14, 0.44) improvement in ACQ score, a 6.1 point improvement in SGRQ (95% CI 3.2, 9.1), and a 45% reduction in exacerbation (RR=0.55; 95%CI 0.44, 0.69) with mepolizumab as compared to placebo. Mepolizumab improved asthma control, QoL (measured by SGRQ) and effectively reduced exacerbations in patients with SA and comorbid upper airways disease." @default.
- W2912120796 created "2019-02-21" @default.
- W2912120796 creator A5002602563 @default.
- W2912120796 creator A5018919281 @default.
- W2912120796 creator A5020942275 @default.
- W2912120796 creator A5029484812 @default.
- W2912120796 creator A5076439834 @default.
- W2912120796 date "2019-02-01" @default.
- W2912120796 modified "2023-09-27" @default.
- W2912120796 title "Mepolizumab improves patient outcomes and reduces exacerbations in severe asthma patients with comorbid upper airways disease" @default.
- W2912120796 doi "https://doi.org/10.1016/j.jaci.2018.12.286" @default.
- W2912120796 hasPublicationYear "2019" @default.
- W2912120796 type Work @default.
- W2912120796 sameAs 2912120796 @default.
- W2912120796 citedByCount "5" @default.
- W2912120796 countsByYear W29121207962020 @default.
- W2912120796 countsByYear W29121207962021 @default.
- W2912120796 crossrefType "journal-article" @default.
- W2912120796 hasAuthorship W2912120796A5002602563 @default.
- W2912120796 hasAuthorship W2912120796A5018919281 @default.
- W2912120796 hasAuthorship W2912120796A5020942275 @default.
- W2912120796 hasAuthorship W2912120796A5029484812 @default.
- W2912120796 hasAuthorship W2912120796A5076439834 @default.
- W2912120796 hasBestOaLocation W29121207961 @default.
- W2912120796 hasConcept C126322002 @default.
- W2912120796 hasConcept C142724271 @default.
- W2912120796 hasConcept C159110408 @default.
- W2912120796 hasConcept C1862650 @default.
- W2912120796 hasConcept C204787440 @default.
- W2912120796 hasConcept C27081682 @default.
- W2912120796 hasConcept C2776042228 @default.
- W2912120796 hasConcept C2777014857 @default.
- W2912120796 hasConcept C2777037409 @default.
- W2912120796 hasConcept C2777832160 @default.
- W2912120796 hasConcept C2779159551 @default.
- W2912120796 hasConcept C2779951463 @default.
- W2912120796 hasConcept C2908647359 @default.
- W2912120796 hasConcept C71924100 @default.
- W2912120796 hasConcept C99454951 @default.
- W2912120796 hasConceptScore W2912120796C126322002 @default.
- W2912120796 hasConceptScore W2912120796C142724271 @default.
- W2912120796 hasConceptScore W2912120796C159110408 @default.
- W2912120796 hasConceptScore W2912120796C1862650 @default.
- W2912120796 hasConceptScore W2912120796C204787440 @default.
- W2912120796 hasConceptScore W2912120796C27081682 @default.
- W2912120796 hasConceptScore W2912120796C2776042228 @default.
- W2912120796 hasConceptScore W2912120796C2777014857 @default.
- W2912120796 hasConceptScore W2912120796C2777037409 @default.
- W2912120796 hasConceptScore W2912120796C2777832160 @default.
- W2912120796 hasConceptScore W2912120796C2779159551 @default.
- W2912120796 hasConceptScore W2912120796C2779951463 @default.
- W2912120796 hasConceptScore W2912120796C2908647359 @default.
- W2912120796 hasConceptScore W2912120796C71924100 @default.
- W2912120796 hasConceptScore W2912120796C99454951 @default.
- W2912120796 hasIssue "2" @default.
- W2912120796 hasLocation W29121207961 @default.
- W2912120796 hasOpenAccess W2912120796 @default.
- W2912120796 hasPrimaryLocation W29121207961 @default.
- W2912120796 hasRelatedWork W1486932876 @default.
- W2912120796 hasRelatedWork W1599031459 @default.
- W2912120796 hasRelatedWork W1996417170 @default.
- W2912120796 hasRelatedWork W2022027560 @default.
- W2912120796 hasRelatedWork W2074477277 @default.
- W2912120796 hasRelatedWork W2799632724 @default.
- W2912120796 hasRelatedWork W2961277609 @default.
- W2912120796 hasRelatedWork W3033502977 @default.
- W2912120796 hasRelatedWork W3111715325 @default.
- W2912120796 hasRelatedWork W4220860952 @default.
- W2912120796 hasVolume "143" @default.
- W2912120796 isParatext "false" @default.
- W2912120796 isRetracted "false" @default.
- W2912120796 magId "2912120796" @default.
- W2912120796 workType "article" @default.